Utility of HBsAg measuring system by BLEIA<sup>®</sup>-1200, a highly sensitive immunoassay system

DOI Web Site Web Site 8 References
  • Yatsuhashi Hiroshi
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Nakamura Mika
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Kugiyama Yuki
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Sasaki Ryu
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Bekki Shigemune
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Hashimoto Satoru
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Bae Sung-Kwan
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Otani Masashi
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Saeki Akira
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Nagaoka Shinya
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Komori Atsumasa
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Abiru Seigo
    Clinical Research Center, National Hospital Organization Nagasaki Medical Center
  • Minekawa Takayuki
    Eiken Chemical Co., Ltd
  • Kamiyama Michinobu
    Eiken Chemical Co., Ltd
  • Okuma Hiroshi
    Eiken Chemical Co., Ltd

Bibliographic Information

Other Title
  • 生物発光を用いた高感度免疫測定装置BLEIA<sup>®</sup>-1200によるHBs抗原測定の有用性
  • 生物発光を用いた高感度免疫測定装置BLEIA-1200によるHBs抗原測定の有用性
  • セイブツ ハッコウ オ モチイタ コウカンド メンエキ ソクテイ ソウチ BLEIA-1200 ニ ヨル HBs コウゲン ソクテイ ノ ユウヨウセイ
  • Utility of HBsAg measuring system by BLEIA®-1200, a highly sensitive immunoassay system

Search this article

Abstract

The utility of BLEIA®-1200, an immunoassay system which performs highly sensitive measurement using bioluminescence and its dedicated reagent BLEIA®' Eiken' HBsAg were reviewed. The detection limit was 0.005 IU/ml which was 6 to 10 times higher in sensitivity than the conventional quantitative reagents. The correlation with chemiluminescent immunoassay (CLIA) was favorable with r=0.983, and parallel shifts were seen in treatment progress. In acute hepatitis B infection, BLEIA® showed positive result as long as HBV-DNA was positive even after CLIA became negative. Although one case in CLIA negative non-B hepatitis patients gave a discrepant result in BLEIA®, it was determined as a case of previous HBV infection since HBcAb was positive. This discrepancy may have been due to the difference in reagent sensitivities. BLEIA® reagent' s utility is suggested in screening for HBV infection, early diagnosis in early phase in HBV infection, early detection in de novo hepatitis infection.

Journal

  • Kanzo

    Kanzo 55 (9), 521-529, 2014

    The Japan Society of Hepatology

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top